alexa Outcome of Isoniazid Preventive Therapy in Adults Living with HIV in Penang, Malaysia | OMICS International
ISSN: 2329-8731
Journal of Infectious Diseases & Preventive Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Outcome of Isoniazid Preventive Therapy in Adults Living with HIV in Penang, Malaysia

Lim CL1*, Wong PS1, Pereirasamy L2, Ang PP2, Leong KN1 and Chow TS1

1Department of Infectious Diseases, Penang General Hospital, Penang, Malaysia

2Department of Medicine, Seberang Jaya Hospital, Penang, Malaysia

*Corresponding Author:
CL Lim
Department of Infectious Diseases
Penang General Hospital, Penang
Tel: 60133620081
E-mail: [email protected]

Received date: July 19, 2016; Accepted date: August 27, 2016 ; Published date: September 03, 2016

Citation: Lim CL, Wong PS, Pereirasamy L, Ang PP, Leong KN, et al. (2016) Outcome of Isoniazid Preventive Therapy in Adults Living with HIV in Penang, Malaysia. J Infect Dis Preve Med 4:133. doi: 10.4172/2329-8731.1000133

Copyright: © 2016 Lim CL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Infectious Diseases & Preventive Medicine


Isoniazid preventive therapy (IPT) is a recommended strategy by World Health Organization (WHO) for prevention of active TB infection in people living with HIV. However, data on feasibility and outcome of IPT in Asia are limited. We conducted a retrospective study of 242 HIV patients in Penang who were commenced on IPT between 2011 and 2014, at two HIV specialist clinics in Penang General Hospital and Seberang Jaya Hospital. We evaluated the outcome of IPT in terms of completion rate, adverse events and incidence of active TB. A total of 193 (81.1%) patients completed 6 months of IPT. Patients receiving concurrent highly active antiretroviral therapy (HAART) had significantly higher IPT completion rate (86.1%) compared to those who were not on HAART (67.7%). Major reasons for non-completion were adverse events (21/45) and defaulting from follow-up (17/45). Forty patients (18%) developed adverse events, including hepatotoxicity (8.56%) and rash (5.41%). The risk factors for hepatotoxicity were Hepatitis B/C co-infection and alanine transaminase above the upper limit of normal at baseline. None of our patients who received IPT developed active TB up to 1 year of follow-up. IPT is feasible and relatively safe. Coadministration of IPT with HAART does not compromise safety or compliance.


HIV; IPT; Isoniazid; Tuberculosis; Hepatitis


HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new mycobacterium tuberculosis infection. The risk of developing TB is between 20 to 37 times greater in people living with HIV (PLHIV) than among those who do not have HIV infection [1]. Morbidity and mortality from drug-sensitive and drug-resistant TB among PLHIV are unacceptably high [2,3].

Highly active antiretroviral treatment (HAART) significantly but not entirely reduces the risk of TB disease [4]. In HIV infected patients, isoniazid preventive therapy (IPT) reduces reactivation of latent TB infection, both in industrialized countries [57] as well as in developing countries [8-10]. In 1993, the World Health Organization (WHO) first issued a policy statement that recognized the efficacy of TB preventive therapy and recommended IPT for PLHIV [11-13]. The WHO recommended regimen for TB preventive therapy in PLHIV is isoniazid for at least 6 months [14].

The IPT program has since been implemented worldwide. The outcome of IPT has been predominantly determined in clinical trials and observational studies in African countries. Data on feasibility, efficacy, safety and completion rates of IPT among PLHIV in Asia are limited. There are specific concerns about adverse events of isoniazid in those with concurrent HAART.


In this study we assessed the demographics and compliance of PLHIV taking IPT in two hospital-based HIV clinics in Penang, Malaysia. We also aimed to determine the rates and contributory factors of adverse events, as well as the incidence of active TB within 1 year after initiation of IPT.


Study design and population

This retrospective cohort study was conducted at two HIV specialist clinics in Penang General Hospital and Seberang Jaya Hospital respectively, where IPT has been implemented since 2011. Subjects included HIV patients who were commenced on IPT between 2011 and 2014, with or without concurrent HAART.


All subjects underwent TB symptom screening (fever, cough, weight loss and night sweats for the past 4 weeks) and further investigations (including chest X-ray) if indicated. Chest X-ray was not a mandatory screening before initiating IPT. Tuberculin skin test (Mantoux) was not required for IPT eligibility. After ruling out active TB, IPT consisting of isoniazid 300 mg and pyridoxine 20 mg daily was started for 6 month duration in accordance with WHO recommendations. HAART was initiated before, during or after IPT based on indication and clinical appropriateness. Follow-up visits during IPT were monthly to three monthly. Patients were monitored for TB symptoms, compliance and adverse events including elevated alanine transaminase (ALT). Upon completion of IPT, patients would resume routine HIV follow-up visits with regular screening of TB symptoms.


The outcome of interest in this study was the IPT completion rate, incidence of adverse events and occurrence of active TB infection at 1 year follow-up. Patients who were lost to follow-up or expired (due to causes not related to IPT) were excluded from the adverse events and TB occurrence analysis. Patients who were transferred to other hospitals were excluded from all outcome analysis.

Hepatotoxicity was defined as ALT level of at least 2 times the upper limit of normal (ULN) [15]. The severity of hepatotoxicity was graded based on a system defined by AIDS Clinical Trials Group (ACTG) (Table 1).

Feature Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
ALT (ULN) <1.25 1.25-2.5 >2.5-5.0 >5.0-10 >10
AST (ULN) <1.25 1.25-2.5 >2.5-5.0 >5.0-10 >10
Alkaline Phosphatase (ULN) <1.25 1.25-2.5 >2.5-5.0 >5.0-10 >10
GGT (ULN) <1.25 1.25-2.5 >2.5-5.0 >5.0-10 >10
Bilirubin (ULN) Normal >1.0-1.5 >1.5-2.5 >2.5-5 >5

Table 1: AIDS Clinical Trials Group (ACTG) Severity Grading of Drug Induced Liver Injury.

Data collection and analysis

Information on patient demographics, baseline characteristics (CD4 count, HAART regimen, ALT level, viral hepatitis co-infection etc.) and outcome was retrieved from patients’ clinic records and data sheets. Data integrity was assessed and descriptive statistics were generated. Relative risks (RR) were determined for the cohort analysis of IPT non-completion and adverse events.


We started IPT for 242 patients, of whom 204 (84.3%) were males and their mean age was 37.4 ± 10.9 years. Their median baseline CD4 count was 315.5 cells/uL (IQR, 327); 31.4% had a CD4 count less than 200 cells/uL and 72.7% were receiving HAART during IPT. Baseline chest X-rays were done for 85 (35.1%) patients. Majority of patients (229/242, 94.6%) had normal baseline ALT level (< ULN), while 12 (5%) patients had slightly higher ALT level (1-1.9 x ULN) at the start of IPT. Only 1 patient had baseline ALT more than 2 times the ULN. Twenty nine (12%) patients were co-infected with viral hepatitis (10 had Hepatitis B, 18 had Hepatitis C, and 1 had both Hepatitis B and C) (Table 2).

Baseline Covariates N=242; No. (%)
Number of patients
Penang General Hospital 210 (86.8%)
Seberang Jaya Hospital 32 (13.2%)
Age (years) [Mean=37.4 ± 10.9]
=35 109 (45.0%)
>35 133 (55.0%)
Male 204 (84.3%)
Female 38 (15.7%)
Chinese 129 (53.3%)
Malay 63 (26.0%)
Indian 38 (15.7%)
Other 12 (5.0%)
CD4 Count (cells/uL) [Median=315.5, IQR, 327]
<200 76 (31.4%)
200-349 59 (24.4%)
350-499 52 (21.5%)
500 & above 55 (22.7%)
Concurrent HAART
Yes 176 (72.7%)
No 66 (27.3%)
Baseline Chest X-Ray
Done 85 (35.1%)
Not done* 157 (64.9%)
Baseline ALT
<ULN 229 (94.6%)
1 – 1.9 x ULN 12 (5.0%)
2 – 2.9 x ULN 1 (0.4%)
Viral Hepatitis co-infection
No 213 (88.0%)
Hepatitis B 10 (4.2%)
Hepatitis C 18 (7.4%)
Hepatitis B and C 1 (0.4%)

Table 2: The socio-demographic and baseline characteristics of study cohort

HAART regimens that patients received consisted of Tenofovir- Emtricitabine, Efavirenz (67.1%), Zidovudine- Lamivudine, Efavirenz (14.2%), Zidovudine-Lamivudine, Nevirapine (7.4%), Tenofovir- Emtricitabine, Raltegravir (4.6%) and others (Table 3).

N = 176; No. (%)
Timing of HAART commencement Before IPT 158 (89.8%)
  During IPT 18 (10.2%)
  Tenofovir-Emtricitabine (FDC), Efavirenz 118 (67.1%)
  Zidovudine-Lamivudine (FDC), Efavirenz 25 (14.2%)
  Zidovudine-Lamivudine (FDC), Nevirapine 13 (7.4%)
  Tenofovir-Emtricitabine (FDC), Raltegravir 8 (4.6%)
  Tenofovir-Emtricitabine (FDC), Lopinavir-Ritonavir (FDC) 3 (1.7%)
HAART Regime Tenofovir-Emtricitabine (FDC), Nevirapine 2 (1.1%)
  Stavudine-Lamivudine-Nevirapine (FDC) 3 (1.7%)
  Tenofovir-Emtricitabine (FDC), Rilpivirine 2 (1.1%)
  Others 2 (1.1%)
FDC: Fixed Dose Combination

Table 3: Concurrent HAART during IPT.

Completion Rate

Excluding patients who were transferred to other hospitals, 193 (81.1%) patients completed IPT (Table 4). Major reasons for noncompletion of IPT were adverse events (46.7%), defaulting from followup (37.8%) and poor compliance (6.7%). One patient passed away during 2nd month of IPT due to septic shock, which was not related to TB or IPT. Another patient had interruption of IPT medications due to prescription error. One patient stopped IPT due to pill burden (he was receiving concomitant HAART) and another was worried about side effects (Figure 1).

Outcomes No. (%)
Defaulted IPT and lost to follow-up 15 (6.2%)
Expired during IPT 1 (0.4%)
Transferred to other hospitals during IPT 4 (1.7%)
Completed IPT* Yes 193 (81.1%)
No 45 (18.9%)
Adverse events during IPT** Yes 40 (18%)
No 182 (82%)
Occurrence of active TB infection at 1 year follow-up** Yes 0 (0%)
No 222 (100%)

Table 4:Summaryof studyoutcomes.


Figure 1: Reasons for non-completion of PTI.

Completion rate was higher among patients with concurrent HAART (149/173, 86.1%) compared to HAART naïve patients (44/65,67.7%) (P=0.001). Co-administration of HAART significantly reduced the incidence of non- completion of IPT (RR, 0.43; 95% confidence interval [CI], 0.3-0.7; P< 0.005). Age greater than 35 years, male gender and CD4 count less than 200 cells/uL were not associated with non-completion of IPT (Table 5).

Fraction of patients with non-completion of IPT   RR (95% CI)
>35 24/130 0.95 (0.6-1.6) 0.979
=35 21/108 1
Male 39/201 1.20 (0.6 - 2.6) 0.821
Female Jun-37 1
CD4 count
< 200 15/75 1.09 (0.6 - 1.9) 0.909
= 200 30/163 1
Concurrent HAART
Yes 24/173 0.43 (0.3 - 0.7) <0.005
No 21/65 1

Table 5: Risk factors associated with non-completion of IPT.

Adverse Events

Forty patients (18%) developed adverse events during IPT (Table 4). There were 19 incidences of hepatotoxicity, 12 rashes, 6 gastrointestinal (GI) symptoms (diarrhea, nausea), 5 peripheral neuropathy and 2 central nervous system (CNS) symptoms (sleepiness, lightheadedness) (Figure 2).


Figure 2: Adverse events 7occurred during IPT.

The incidence rate of hepatotoxicity was 8.56%. Significant risk factors for hepatotoxicity during IPT were Hepatitis B and/or C coinfection (RR, 3.99; 95% CI, 1.7-9.4; P< 0.01) and baseline ALT level = ULN (RR, 8.85; 95% CI, 4.1-19.0; P< 0.001). Concurrent HAART, age greater than 35 years, male gender and CD4 count less than 200 cells/ uL were not associated with the occurrence of hepatotoxicity (Table 6).

Fraction of patients
with hepatotoxicity*
RR (95% CI) P value
>35 10/120 0.94 (0.4 -2.2) 0.912
=35 9/102 1.0
Male 17/189 1.48 (0.4 -6.0) 0.827
Female  2/33 1.0
CD4 <200  7/68 1.32 (0.5 -3.2) 0.723
CD4 = 200 12/154 1.0
Baseline ALT
= ULN**  6/11 8.85 (4.1 -19.0) <0.001
<ULN 13/211 1.0
Concurrent HAART
Yes 13/166 0.73 (0.3 -1.8) 0.696
No  6/56 1.0
Hep B/C co-infection
Yes  6/23 3.99 (1.7-9.4) <0.01
No 13/199 1.0

Table 6: Risk factors associated with hepatotoxicity during IPT.

The severity of liver injury sustained was either Grade 1 (6 patients) or Grade 2 (13 patients), all of which were asymptomatic and reversible. Ten patients (52.6%) out of those who developed hepatotoxicity managed to complete IPT without complication despite significant elevation of ALT level (Table 7).

No Age Gender Baseline CD4 count (cells/uL) Concurrent HAART Exposure to NNRTIs Viral Hepatitis Co-infection Baseline ALT (Relative to ULN) Highest elevated level of ALT (Relative to ULN)* Grade of Severity** Completed IPT
1 40 M 101 Yes NVP No <ULN 2.9 x 2 No
2 38 M 84 Yes EFV Hep C <ULN 4 x 2 No
3 37 M 18 Yes EFV No <ULN 2 x 1 Yes
4 32 M 534 No No No <ULN 3.5 x 2 Yes
5 38 M 36 Yes EFV No <ULN 2.2 x 1 Yes
6 33 M 449 No No No <ULN 4.6 x 2 No
7 37 M 147 Yes EFV Hep B <ULN 2.6 x 2 Yes
8 28 M 414 Yes EFV No <ULN 2.6 x 2 No
9 34 M 419 No No Hep C <ULN 2.2 x 1 Yes
10 34 M 550 Yes EFV Hep B & C <ULN 2.9 x 2 Yes
11 42 M 12 Yes EFV No 1 x 2.6 x 2 Yes
12 25 M 274 Yes EFV No <ULN 4 x 2 No
13 30 M 345 Yes EFV No <ULN 3.8 x 2 No
14 27 M 627 No No No 1.4 x 3.1 x 2 No
15 61 F 437 No No No <ULN 3.8 x 2 Yes
16 45 M 141 Yes EFV Hep C 1 x 2 x 1 Yes
17 33 M 300 Yes EFV No 1.4 x 2.1 x 1 Yes
18 37 F 300 Yes No No 1.9 x 2.5 x 1 No
19 48 M 636 No No Hep C 1 x 2.7 x 2 No

Table 7: Characteristics of study cohort who developed hepatotoxicity during IPT (N=19).

Skin rash occurred at a rate of 5.41%. There was no significant predisposing factor for the development of rashes (Table 8). No correlation analysis was done for other adverse events as the incidence was low.

Fraction of patients with skin rash RR (95% CI) P value
>35 4/120 0.42 (0.1 - 1.3) 0.237
=35 8/102 1.0
Male 12/189 - (8 - 0.0) 0.284
Female 0/33 1.0
CD4 <200  5/68 1.62 (0.5 - 4.9) 0.596
CD4 = 200 7/154 1.0
Concurrent HAART
Yes 8/166 0.67 (0.2 - 2.2) 0.747
No  4/56 1.0

Table 8:Risk factors associatedwith skin rash duringIPT.

TB Occurrence

None of the patients who were exposed to IPT (including those who stopped IPT prematurely) developed active TB infection at 1 year follow-up (Table 4).

Sub-analysis on cohort who were lost to follow-up

There were 15 (6.2%) patients who lost to follow-up during IPT. This was significantly associated with patients co-infected with Hepatitis C (RR, 3.73; 95% CI, 1.4-9.8; P< 0.05). Patients with concurrent HAART were less likely to be lost to follow-up (RR, 0.25; 95% CI, 0.1-0.6; P< 0.01). There was no clear association with age, gender or baseline ALT (Table 9).

Fraction of patients who lost to follow- up RR (95% CI) P value
>35 8/128 0.97 (0.4 - 2.6) 0.831
=35 7/109 1.0  
Male 12/201 0.72 (0.2 - 2.4) 0.868
Female 3/36 1.0  
CD4 <200 6/74 1.47 (0.5 - 4.0) 0.638
CD4 = 200 9/163 1.0  
Concurrent HAART      
Yes 6/172 0.25 (0.1 - 0.6) <0.01
No 9/65 1.0  
Baseline ALT 6/172    
= ULN 2/12 2.88 (0.7 - 11.4) 0.368
< ULN 13/225 1.0  
Hep C co-infection*      
Yes 5/28 3.73 (1.4 - 9.8) < 0.05
No 10/209 1.0  

Table 9: Risk factors associated with patients lost to follow-up during IPT.


Studies have consistently shown early initiation of HAART and immune reconstitution prolongs life expectancy of HIV patients, to the extent of approaching that of general population [16]. The START (Strategic Timing of Anti- Retroviral Treatment) study, a large-scale randomized clinical trial has established that early antiretroviral treatment at CD4 count above 500 cells/uL significantly reduces the rates of serious AIDS and non-AIDS events [17]. Many HIV guidelines including the WHO have been revised to recommend early initiation of HAART regardless of presenting CD4 cell count or clinical stage [18].

In our study, 72.7% of our patients were started on HAART before or during IPT. As majority of HIV patients are receiving HAART, it is important to study the outcome of co-administration of IPT with HAART in terms of compliance and adverse events.

The overall completion rate of IPT in our study was acceptable and comparable to previous studies. Despite the increase in pill burden, IPT was well tolerated with concurrent HAART. In fact, there was a significantly higher completion rate in patients with concurrent HAART. We attributed this observation to the pre-HAART counseling which emphasized on strict drug adherence. Most of these patients were mentally prepared and committed to be on long term medications.

Although the benefit of IPT among PLHIV is well established, there were concerns about adverse events of isoniazid, particularly when co-administered with HAART. Isoniazid and NNRTI (nonnucleoside reverse transcriptase inhibitor), a commonly used class of antiretroviral drug, shared similar side effect profiles. They are known to cause hepatotoxicity and rash. A prospective study in Botswana of 1,995 PLHIV on IPT observed 1.1% rate of severe isoniazid-associated hepatitis, which was similar to rates in HIV-uninfected populations. HAART was received by 480 participants but was not statistically associated with isoniazid induced hepatitis (RR, 1.56; 95% CI, 0.62- 3.9) [19]. A South African study of 818 men and 50 women reported no statistically significant association between Grade 3 or 4 hepatitis in PLWH receiving IPT and efavirenz based anti-retroviral therapy (hazard ratio,0.83, 95% CI, 0.20–3.4) [20]. These observations were consistent with our study finding that patients concomitantly taking HAART and IPT had no significantly increased risk of hepatotoxicity (RR, 0.73; 95% CI, 1.8-0.3), despite majority of them were on NNRTI (efavirenz or nevirapine) based HAART. In addition, all our reported hepatotoxicity was either mild or moderate (severity Grade 1 to 2) and reversible. More than half of our patients with elevated ALT managed to complete IPT without any complications. The incidence of skin rash was low and not associated with co-administration of HAART.

Patients with Hepatitis B/C co-infection or baseline ALT more than ULN had to be closely monitored for risk of hepatotoxicity as shown in our study. However, these patients should not be denied IPT as the benefit still outweighed the risk.

Majority of our cohort had baseline CD4 count less than 350 cells/ uL and HAART was strongly indicated. Thirty- one point four percent (31.4%) of them had CD4 count less than 200 cells/uL, which rendered them very susceptible to TB reactivation. A meta-analysis of randomized clinical trials that assigned 7619 HIV patients to IPT or placebo found an overall 35% of TB risk reduction (RR,0.65, 95% CI, 0.51-0.84) in all participants [21]. Our cohort who received IPT did not develop active TB infection up to 1 year of follow-up. However, we could not attribute this finding solely to IPT as this was not a comparative study against IPT naïve patients and most of our patients were co-administered with HAART. It is well accepted that immune reconstitution after HAART reduced the risk of reactivation of TB. In a cohort study in South Africa, the number of TB cases averted by HAART was greatest in patients with WHO stage 3 or 4 (18.8 averted cases per 100 patientyears, adjusted rate ratio 0.22 [0.09–0.41]; p=0.03) and in those with CD4 count of less than 200 cells/µL (14.2 averted cases per 100 patientyears, adjusted rate ratio 0.18 [0.07–0.47]; p< 0.0001) [4]. In addition, evidence from two retrospective studies that examined the benefit of TB prevention in PLHIV receiving HAART and IPT indicated that the protection conferred by the combination was additive [22,23].

Six point two percent (6.2%) of patients were lost to followup during IPT. A significant proportion of these patients were coinfected with Hepatitis C. They comprised of ex-intravenous drug users with poor social- economic background and in general have a tendency to default treatment. We also suspect a few of them may have developed adverse events, which led to self-discontinuation of IPT and subsequent were lost to follow-up. The phenomenon of patients with concurrent HAART having significant lower risk of defaulting follow-up likely reflects the effectiveness and importance of our pre-HAART counseling.

Although international guidelines on the timing of initiation of IPT and HAART are unsettled, we suggest that IPT can precede HAART initiation if a patient’s CD4 count is still high (more than 350 cells/uL). Commencing IPT first would allow HAART naïve patients to undergo pill training prior to initiation of HAART, which requires life-long drug adherence and compliance. Conversely, in patients with low CD4 count (less than 350 cells/uL) or have previous opportunistic infections, immune reconstitution should be the priority. Hence IPT should be deferred until stabilization on HAART.


IPT is feasible and relatively safe among our local PLHIV. IPT and HAART can be co-administered to give additive prophylaxis against reactivation of TB and has not been shown to compromise safety or compliance in our study. Larger and longer comparative studies are needed to determine the outcome of IPT in our local HIV population. Other potential risk factors of isoniazid-hepatotoxicity such as alcohol and bactrim usage should be evaluated. Future studies also need to address the risk of developing drug-resistant TB after exposure to IPT.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this manuscript.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 8391
  • [From(publication date):
    November-2016 - May 27, 2018]
  • Breakdown by view type
  • HTML page views : 8291
  • PDF downloads : 100

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7